CDEK
← All drugs Report issue

oliceridine

Trade name: Olinvyk

Small moleculeapprovedFast Track FDA

Approved

Aug 7, 2020

Oliceridine, sold under the brand name Olinvyk, is an opioid medication that is used for the treatment of moderate to severe acute pain in adults. It is given by intravenous (IV) injection. — Wikipedia

Clinical trial activity

33 trials · 22 clinical orgs · 1 marketing orgs

Phase 1
6
Phase 2
10
Phase 3
5
Phase 4
9

Earliest trial started Jan 1, 2012 (NCT01514578)

Timeline

2010s

  1. Jan 1, 2012

    Trevena Inc. — Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2014

    Trevena Inc. — Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2015

    Trevena Inc. — Earliest Phase 3 Sponsor(trial)

2020s

  1. Aug 7, 2020

    Trevena Inc. — Earliest FDA Approval

  2. Aug 7, 2020

    Trevena Inc. — Marketing Organization

  3. Aug 7, 2020

    Trevena Inc. — NDA Secondary Org

  4. Aug 7, 2020

    Trevena Inc. — NDA Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedFast trackAug 7, 2020

Chemistry & pharmacology

Loading structure…

SMILES

COc1ccsc1CNCC[C@@]1(c2ccccn2)CCOC2(CCCC2)C1
Mol. weight
386.56 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only

Oral

No

Parenteral

Yes

Topical

No

Black box warning

Sources

Also known as

  • ((3-methoxythiophen-2-yl)methyl)((2-(9-(pyridin-2-yl)-6-oxaspiro(4.5)decan-9-yl)ethyl))amine
  • oliceridine
  • oliceridine
  • oliceridine
  • trv130
  • trv130
  • trv130
  • trv-130
  • trv-130

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07307495N/AJan 1, 2026Xijing Hospital
NCT07187765N/ASep 22, 2025Huazhong University of Science and Technology
NCT07154979N/ASep 4, 2025Huazhong University of Science and Technology
NCT07112157N/AAug 31, 2025Henan Provincal People's Hospital
NCT07018375Phase 4Aug 1, 2025Tianjin Medical University
NCT07097038N/AJul 31, 2025Henan Provincal People's Hospital
NCT07026162Phase 4Jul 21, 2025Central South University
NCT06668298N/ANov 30, 2024Henan Provincal People's Hospital
NCT06990893N/ANov 11, 2024Anqing Municipal Hospital
NCT06619145Phase 4Nov 1, 2024Nanjing Medical University
NCT06530563Phase 4Aug 31, 2024Central South University, Wu Jieping Medical Foundation
NCT06411665Phase 4Jul 2, 2024Peking University
NCT06454292Phase 4Jun 30, 2024Sichuan University
NCT06458400Phase 4Jun 6, 2024Jiao Tong University
NCT06409689N/AJun 1, 2024Huazhong University of Science and Technology
NCT06467409Phase 2Jan 26, 2024Luye Pharma
NCT07306702Phase 4Jul 1, 2023Shenyang Sixth People's Hospital
NCT06204120Phase 2Nov 25, 2022Luye Pharma
NCT05465226Phase 4Aug 31, 2022University of Tennessee
NCT05509868Phase 3Jul 20, 2022Pharmbio Korea, University of Ulsan
Showing 20 of 33 trials
Page 1 / 2

Organizations

Research & Development (22)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Trevena Inc.For profit101032012
Luye PharmaFor profit4422021
Henan Provincal People's HospitalAcademic/Hospital3312024
Huazhong University of Science and TechnologyAcademic/Hospital3312024
Central South UniversityAcademic/Hospital2212024
Anqing Municipal HospitalAcademic/Hospital1112024
ICONFor profit1012012
Indiana UniversityAcademic/Hospital1012015
Jiao Tong UniversityAcademic/Hospital1112024
Kestrel BiologicFor profit1012015
Lotus Clinical ResearchFor profit1012014
Nanjing Medical UniversityAcademic/Hospital1112024
Peking UniversityAcademic/Hospital1112024
Pharmbio KoreaFor profit1112022
Shenyang Sixth People's HospitalAcademic/Hospital1112023
Sichuan UniversityAcademic/Hospital1112024
The Cleveland ClinicAcademic/Hospital1112021
Tianjin Medical UniversityAcademic/Hospital1112025
University of TennesseeAcademic/Hospital1112022
University of UlsanAcademic/Hospital1012022
22 organizations
Page 1 / 2

Marketing (3)

OrganizationOrg typeRelationshipDate
Trevena Inc.For profitMKTGAug 7, 2020
Trevena Inc.For profitNDA2Aug 7, 2020
Trevena Inc.For profitNDAAug 7, 2020